Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RET fusions observed in lung and colorectal cancers are sensitive to ponatinib

3 Jul 2018

Abstract excerpt

// Joseph M. Gozgit 1 , Tzu-Hsiu Chen 1 , Youngchul Song 1 , Scott Wardwell 1 , Frank Wang 1 , Jie Cai 2 , Henry Li 2 , Henrik Edgren 3 , Victor M. Rivera 1 and Justin Pritchard 1, 4 1 ARIAD Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA 2 Crown Bioscience, Shanghai, P.R. China 3 Medisapiens Ltd., Helsinki, Finland 4 Department of Biomedical Engineering,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Cancer Treatments and Studies
Share to Gastric Cancer Management and Outcomes
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30038711
DOI: 10.18632/oncotarget.25664

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RET fusions observed in lung and colorectal cancers are sensitive to ponatinibPMID 30038711Read ↗

RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future.Semantic proximity Read ↗

Landscape of potentially targetable receptor tyrosine kinase fusions in diverse cancers by DNA-based profilingSemantic proximity Read ↗

Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.Semantic proximity Read ↗

A Retrospective, Multicenter Analysis Within the National Network Genomic Medicine Lung Cancer in Germany to Detect RET Fusions as a Possible Mechanism of Resistance in Patients With EGFR Mutations.Semantic proximity Read ↗

Targeting RET alterations in non-small cell lung cancer.Semantic proximity Read ↗

Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling.Semantic proximity Read ↗

Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.Semantic proximity Read ↗

RET Fusion-Positive Lung Adenocarcinoma: Partner-Specific Clinicopathological Characteristics, Co-Mutation Profiles, and Implications for Targeted and Immunotherapy.Semantic proximity Read ↗

Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subsetSemantic proximity Read ↗

A Performance Comparison of Commonly Used Assays to Detect RET FusionsSemantic proximity Read ↗

Identification of RET fusions in a Chinese multicancer retrospective analysis by next‐generation sequencingSemantic proximity Read ↗

Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinibSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.